The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Novavax expects 2024 total revenues to be in the range of $650-$700 million, down from its previously issued guidance of $700 ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

The three major indexes had rallied to record highs since the Nov. 5 U.S. election as ... Biotech firm Novavax dropped after ...

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax Gets FDA Nod to Test Vaccines The third-quarter results come a day after the drugmaker announced the U.S. Food and ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. ( Washington Post) Air purifiers in residential aged-care facilities did not reduce the incidence of acute respiratory ...

The company is banking on revenue from its Sanofi deal and vaccines in development, including an experimental COVID-flu ...

Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 ...